ASH 2021: Updates in MM

ASH 2021: Updates in MM

PROMISE Study Provides ‘Most Precise’ Estimates of MGUS in High-Risk Patients

The PROMISE study revealed a 10% incidence of monoclonal gammopathy of undetermined significance among patients at high risk of multiple myeloma.

Cancer Therapy Advisor
COVID-19 Vaccines Less Effective in Patients With Multiple Myeloma

COVID-19 vaccines appear less effective in patients with multiple myeloma, according to a retrospective analysis presented at the 2021 ASH Annual Meeting.

Cancer Therapy Advisor
Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma

Molecular and genetic research has advanced the categorization of different risk groups in patients with smoldering myeloma.

The ASCO Post

Adding Elotuzumab to Myeloma Treatment Regimens Does Not Improve Outcomes

Adding elotuzumab to an induction and consolidation regimen of lenalidomide, bortezomib, and dexamethasone, and to a lenalidomide maintenance regimen, does not improve...

Hematology Advisor
‘High Prevalence’ of Smoldering Myeloma Observed in Nationwide Screening Study

A nationwide screening study suggests the prevalence of SMM is 0.5% among individuals age 40 or older, and more than one-third of patients have intermediate- or high-risk SMM.

Cancer Therapy Advisor
Isatuximab/RVd Meets Primary Endpoint of MRD Negativity for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma

For the first-line treatment of newly diagnosed, transplant-eligible patients with multiple myeloma, the achievement of MRD negativity was significantly greater when the anti-CD38 monoclonal antibo

The ASCO Post
Conditioning Regimens Prior to Autologous Transplantation for Multiple Myeloma

Researchers compared conditioning regimens to determine whether outcomes for patients with multiple myeloma undergoing autologous stem cell transplantation could be improved.

Hematology Advisor
Antibody Response to COVID-19 Vaccination in Patients With Myeloid and Lymphoid Neoplasms

According to a study presented at ASH 2021, about 15% of people with blood cancers and other blood disorders had no vaccination-related antibodies after receiving a COVID-19 vaccine. 

The ASCO Post
Ixazomib and Daratumumab Demonstrate Tolerable Safety for Elderly Patients with Relapsed/Refractory MM

According to new data, combination ixazomib and daratumumab, without dexamethasone, was tolerable in elderly and frail patients with R/R MM.

Oncology Learning Network
Safety and Tolerability Analysis of Melflufen plus Dexamethasone in Patients with Relapsed/Refractory MM

Safety and tolerability data from the OP-103 study found that melflufen plus dexamethasone remained consistent with prior reports; these data were presented at the 63rd ASH Annual Meeting.

Oncology Learning Network
Ixazomib plus Pomalidomide and Dexamethasone Shows Promise in R/R MM

Results of a phase 1/2 multicenter trial showed that twice-weekly ixazomib added to pomalidomide and dexamethasone treatment was a well-tolerated and promising treatment option...

Oncology Learning Network
Adding Venetoclax to Bortezomib and Dexamethasone Improves PFS in Patients with Relapsed/Refractory MM

The phase 3 BELLINI trial found that adding venetoclax to bortezomib and dexamethasone significantly improved response rates and PFS in patients with R/R MM but also led to increased mortality. 

Oncology Learning Network
Venetoclax plus Daratumumab and Dexamethasone Yields Tolerable Safety in Patients with Relapsed/Refractory MM

According to the preliminary results from the expansion cohort of a phase 1/2 trial presented at the ASH Annual Meeting, VenDd demonstrates a tolerable safety profile in patients with R/R MM. 

Oncology Learning Network
New Data in Blood Cancers, Hemophilia, and Other Hematological Disorders to be Presented at ASH 2021

Six oral and 14 poster presentations will be featured during the American Society of Hematology Annual Meeting from December 11-14. 

Ruxolitinib with Steroids Shows Promise in Patients with Relapsed/Refractory MM

According to an ongoing phase 1 trial, ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with R/R MM. 

Oncology Learning Network
Four Oral Presentations from the International Myeloma Foundation-Supported iStopMM Study to Take Center Stage at 2021 ASH Annual Meeting

The IMF today announced that data from the IMF-supported iStopMM study will be showcased in four oral presentations at the 63rd ASH Annual Meeting in Atlanta, Georgia. 

Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma

Researchers compare disease detection of myeloma using contemporary WB MRI and 18F FDG PET/CT protocols and correlate imaging with laboratory estimates of disease burden... 

Radiology: Imaging Cancer

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
rgb(245, 111, 66)
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
rgb(66, 135, 245)
rgb(169, 196, 201)
rgb(125, 127, 130)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
rgb(214, 139, 202)